Thursday 16 October, 2025
Objectives: Alveolar epithelial lining fluid (ELF) has been suggested as an important site of lower respiratory tract infections caused by…
Read morePoster: Drug/Disease Modelling - Infection
Model-based analysis for the screening and ranking of compounds against Plasmodium Falciparum
Thursday 16 October, 2025
Objectives: Malaria is a serious tropical disease caused by infection with Plasmodium protozoa that are transmitted by Anopheles mosquito bite….
Read morePopulation pharmacokinetics of unbound daptomycin in hospital patients with Gram-positive infections
Thursday 16 October, 2025
Objectives: Daptomycin is a lipopeptide antimicrobial agent that exhibits bactericidal activity against a broad range of Gram-positive bacteria, including multidrug-resistant…
Read morePopulation pharmacokinetics of rifampicin in Vietnamese Children with Tuberculous Meningitis
Thursday 16 October, 2025
Introduction/Objective: Tuberculous meningitis (TBM) is the most severe form of extrapulmonary tuberculosis (TB), characterized by the presence of tuberculosis bacteria in…
Read moreA joint pharmacokinetic model of piperacillin/tazobactam including mechanistic renal clearance in critically ill patients
Thursday 16 October, 2025
Objectives: Piperacillin (PIP) is a broad-spectrum β-lactam antibiotic used in combination with the β-lactamase inhibitor tazobactam (TAZ) for the treatment…
Read moreNeopterin dynamics in pediatric patients after miltefosine treatment of visceral leishmaniasis
Thursday 16 October, 2025
Introduction/ObjectivesVisceral leishmaniasis (VL) is the most severe form of the neglected tropical disease leishmaniasis affecting internal organs such as spleen,…
Read moreExploring dose-dependent pharmacokinetics of miltefosine in pediatric visceral leishmaniasis patients from East Africa
Thursday 16 October, 2025
Objectives: Miltefosine is currently the only oral drug available for treatment of the neglected tropical parasitic disease visceral leishmaniasis (VL)….
Read moreBuilding predictive longitudinal PKPD models of antimalarial combinations with Phase 2b data
Thursday 16 October, 2025
Introduction: The World Health Organization recommends artemisinin-based combination therapies against malaria. However, the increasing emergence of resistance jeopardizes the efficacy of…
Read morePopulation PK/PD modeling of blood- and liver-stage activities of cabamiquine in malaria
Thursday 16 October, 2025
Objectives: Cabamiquine is a novel antimalarial under development for the treatment and prevention of malaria, active against multiple life-cycle stages…
Read moreViral Dynamics Model Predicts Clinical Efficacy in Hepatitis C Virus (HCV) Infected Patients Using Viral Kinetic Data from Phase 1 Studies
Thursday 16 October, 2025
Objectives: Grazoprevir (GZR, a protease inhibitor), uprifosbuvir (UPR, a NS5B inhibitor) and ruzasvir (RZR, a NS5A inhibitor) are direct acting antiviral…
Read more